<DOC>
	<DOCNO>NCT01538784</DOCNO>
	<brief_summary>The objective study : - To assess safety , tolerability pharmacokinetics YF476 healthy volunteer . - To select dose dos YF476 detail pharmacodynamic study healthy volunteer .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Doses YF476 , Gastrin Antagonist , Healthy Men</brief_title>
	<detailed_description>YF476 clearly potent selective gastrin/CCK-B antagonist inhibit basal meal-stimulated gastric acid secretion enhance gastric empty liquid meal man . Therefore YF476 might benefit patient reflux oesophagitis . The compound remarkably well tolerate animal toxicity study dose well excess project therapeutic dose patient , merit first administration healthy volunteer . That study use oral route administration describe . Extrapolation data obtain pentagastrin animal suggest single dos less 1mg YF476 active man . However , extrapolation data obtain comparative study H2-antagonists omeprazole animal suggest therapeutic dose patient reflux oesophagitis large , region 10mg . A range single dos use study . The maximum dose 10 time expect therapeutic dose .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Male age 1845 year . No clinically relevant abnormal finding clinical history physical examination screen assessment could interfere objective study make subject 's participation hazardous . No clinically relevant abnormal laboratory value screen evaluation ( Attachment 2 ) . A normal ECG screen examination . A body mass index ( Quetelet index ) range 1930 : Body Mass Index = weight [ kg ] _ height [ ] 2 Normal blood pressure heart rate screen examination , i.e . BP 90150mmHg systolic , 4095mmHg diastolic ; heart rate 40100 beats/min seat position . Subjects must sufficient intelligence understand nature study hazard participation . They must able communicate satisfactorily Investigator participate , comply requirement , entire study . Subjects must give write consent participate reading InformationforVolunteers Leaflet Consent Form , opportunity discus study Investigator deputy . Clinically relevant abnormal history physical finding screen assessment , could interfere objective study safety subject 's participation . Clinically relevant abnormality laboratory value ECG screen evaluation . Presence acute chronic illness history chronic illness sufficient invalidate subject 's participation study make unnecessarily hazardous . Impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease history psychotic mental illness . Participation clinical study new chemical entity prescription medicine within previous 3 month . Presence history drug alcohol abuse , intake 40 unit alcohol weekly . Loss 400ml blood 3 month study , e.g . blood donor . Use prescription medication 30 day study . Use overthecounter medicine 7 day study Blood pressure heart rate outside value specify inclusion criterion ( f ) . Possibility subject cooperate requirement protocol . Evidence drug abuse urine test study entry . Positive test hepatitis B C HIV 1 &amp; 2 . High risk hepatitis HIV infection . History severe allergic disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>YF476</keyword>
	<keyword>gastrin receptor antagonist</keyword>
	<keyword>gastric pH</keyword>
	<keyword>healthy subject</keyword>
</DOC>